ANRO (Alto Neuroscience) Cash per Share: $7.53 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANRO Alto Neuroscience Inc ANRO
12 GF Score
Price $26.72
! 2 Warning Signs
View Full Analysis

What is Alto Neuroscience Cash per Share?

Alto Neuroscience ANRO -2.55% 12 Cash per Share is $7.53 as of Mar. 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Alto Neuroscience's Cash per Share for the quarter that ended in Mar. 2026 was $7.53.


Alto Neuroscience  (NYSE:ANRO) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.


Alto Neuroscience Cash per Share Related Terms


Alto Neuroscience Cash per Share Historical Data

* Premium members only.

The historical data trend for Alto Neuroscience's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alto Neuroscience Cash per Share Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
1.01 1.89 3.23 6.23 5.53

Alto Neuroscience Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.94 5.45 5.07 5.53 7.53
ANRO
12GF Score
Alto Neuroscience Inc ANRO
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alto Neuroscience Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Alto Neuroscience's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Alto Neuroscience's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $7.53 mean?
Alto Neuroscience (ANRO) has a Cash per Share of $7.53 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Alto Neuroscience and its competitors.
Is Alto Neuroscience's Cash per Share too high?
Alto Neuroscience's current Cash per Share is $7.53. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's Cash per Share compare to VOR and CGEM?
Alto Neuroscience's Cash per Share of $7.53 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Alto Neuroscience and its competitors. Alto Neuroscience's current Cash per Share is $7.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current Cash per Share of $7.53. The current Cash per Share is $7.53. Alto Neuroscience's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current Cash per Share is $7.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alto Neuroscience Business Description

Address 650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score

Get the complete analysis for ANRO

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.72
Price